The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratu ...

According to the latest study from BCC Research, "Global Markets for Infectious Disease Treatments" is expected to grow from ...

Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 ...

Innovstone Therapeutics Ltd. has divulged prodrugs of deuterated baloxavir marboxil derivatives acting as polymerase basic protein 2 (PB2) (influenza virus) inhibitors reported to be useful for the ...

Engine Capital urges Avantor board changes; China's Ab&B Bio-Tech shares soar; French chlorine factory fire prompts alert; IO ...

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...

Health secretary Robert F. Kennedy Jr.’s decision to discontinue funding of the development of messenger RNA vaccines is not ...

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

AMA and other medical associations are kicked out of CDC vaccine workgroups Experts are being disinvited from the workgroups that have been the backbone of the Advisory Committee on Immunization ...